KR20180103150A - 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 - Google Patents

암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 Download PDF

Info

Publication number
KR20180103150A
KR20180103150A KR1020187024267A KR20187024267A KR20180103150A KR 20180103150 A KR20180103150 A KR 20180103150A KR 1020187024267 A KR1020187024267 A KR 1020187024267A KR 20187024267 A KR20187024267 A KR 20187024267A KR 20180103150 A KR20180103150 A KR 20180103150A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
sequence shown
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187024267A
Other languages
English (en)
Korean (ko)
Inventor
후아 롱
아론 데이비드 탈
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20180103150A publication Critical patent/KR20180103150A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187024267A 2016-01-25 2017-01-17 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 Ceased KR20180103150A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662286616P 2016-01-25 2016-01-25
US62/286,616 2016-01-25
PCT/IB2017/050244 WO2017130076A1 (en) 2016-01-25 2017-01-17 Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002980A Division KR20210013777A (ko) 2016-01-25 2017-01-17 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합

Publications (1)

Publication Number Publication Date
KR20180103150A true KR20180103150A (ko) 2018-09-18

Family

ID=57956335

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187024267A Ceased KR20180103150A (ko) 2016-01-25 2017-01-17 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
KR1020217002980A Ceased KR20210013777A (ko) 2016-01-25 2017-01-17 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217002980A Ceased KR20210013777A (ko) 2016-01-25 2017-01-17 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합

Country Status (12)

Country Link
US (1) US20190031765A1 (https=)
EP (1) EP3408294A1 (https=)
JP (1) JP6783312B2 (https=)
KR (2) KR20180103150A (https=)
CN (1) CN108473587A (https=)
AU (2) AU2017211540B2 (https=)
BR (1) BR112018014016A2 (https=)
CA (1) CA2955184A1 (https=)
HK (1) HK1259253A1 (https=)
MX (1) MX2018008995A (https=)
RU (1) RU2748949C2 (https=)
WO (1) WO2017130076A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
CN110357961B (zh) * 2018-04-10 2022-08-23 无锡智康弘义生物科技有限公司 抗人4-1bb单克隆抗体及其制备方法和用途
US12054554B2 (en) 2018-04-10 2024-08-06 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2020240360A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
JP2022550297A (ja) 2019-09-25 2022-12-01 ファイザー・インク Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
US20230112470A1 (en) 2020-01-29 2023-04-13 Board Of Regents, The University Of Texas System Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
US20240182593A1 (en) * 2021-05-27 2024-06-06 Yuhan Corporation Ox40 agonist and use thereof
CN118684772A (zh) * 2021-09-09 2024-09-24 广东东阳光药业股份有限公司 抗4-1bb的激动型抗体及其应用
JP2024536133A (ja) 2021-09-29 2024-10-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗ｈｓｐ７０抗体およびその治療的使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US20060153808A1 (en) 2004-11-17 2006-07-13 Board Of Regents, The Universtiy Of Texas System Cancer immunotherapy incorporating p53
CA2610661A1 (en) 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
DK2851374T3 (en) * 2007-12-14 2017-06-19 Bristol Myers Squibb Co Binding molecules to the human OX40 receptor
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
CN103619571B (zh) 2011-06-30 2016-08-17 米其林研究和技术股份有限公司 用于将胎面环安装到轮胎胎体上的方法和设备
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
AU2015264528A1 (en) * 2014-05-21 2016-11-03 Kyowa Hakko Kirin Co., Ltd. Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
PH12017501857B1 (en) * 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments

Also Published As

Publication number Publication date
MX2018008995A (es) 2019-01-10
CA2955184A1 (en) 2017-07-25
EP3408294A1 (en) 2018-12-05
AU2020210145A1 (en) 2020-08-13
HK1259253A1 (zh) 2019-11-29
BR112018014016A2 (pt) 2019-02-05
CN108473587A (zh) 2018-08-31
RU2748949C2 (ru) 2021-06-02
US20190031765A1 (en) 2019-01-31
AU2017211540A1 (en) 2018-07-19
JP2019506403A (ja) 2019-03-07
RU2018127164A3 (https=) 2020-02-28
JP6783312B2 (ja) 2020-11-11
WO2017130076A1 (en) 2017-08-03
AU2017211540B2 (en) 2020-04-30
RU2018127164A (ru) 2020-02-28
KR20210013777A (ko) 2021-02-05

Similar Documents

Publication Publication Date Title
JP6783312B2 (ja) がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
ES2783026T3 (es) Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
JP6586087B2 (ja) Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
TWI663983B (zh) 用於治療癌症之ｐｄ－１拮抗劑及ｖｅｇｆｒ抑制劑之組合
CN107750166B (zh) Pd-l1拮抗剂组合治疗
KR20170004006A (ko) 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
JP7470105B2 (ja) 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ
JP2025004212A (ja) がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
CN115996950A (zh) 抗tnfr2抗体和其用途
CA3195058A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
WO2025128499A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
HK1248530B (en) Pd-l1 antagonist combination treatments

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20180823

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191209

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201029

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191209

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210128